Prenatal Administration of Betamethasone Causes Changes in the T Cell Receptor Repertoire Influencing Development of Autoimmunity

Anna Gieras1*, Christina Gehbauer1, David Perna-Barrull2, Jan Broder Engler3, Ines Diepenbruck1, Laura Glau1, Simon A. Joosse4, Nora Kersten1, Stefanie Klinge1, Hans-Willi Mittrücker1, Manuel A. Friese3, Marta Vives-Pi2,5 and Eva Tolosa1

1Department of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 2Immunology Division, Germans Trias i Pujol Research Institute and Hospital, Universitat Autonoma de Barcelona, Badalona, Spain; 3Institute of Neuroimmunology and Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, Hamburg, Germany; 4Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 5Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain

Prenatal glucocorticoids are routinely administered to pregnant women at risk of preterm delivery in order to improve survival of the newborn. However, in half of the cases, birth occurs outside the beneficial period for lung development. Glucocorticoids are potent immune modulators and cause apoptotic death of immature T cells, and we have previously shown that prenatal betamethasone treatment at doses eliciting lung maturation induce profound thymocyte apoptosis in the offspring. Here, we asked if there are long-term consequences on the offspring’s immunity after this treatment. In the non-obese diabetic mouse model, prenatal betamethasone clearly decreased the frequency of pathogenic T cells and the incidence of type 1 diabetes (T1D). In contrast, in the lupus-prone MRL/lpr strain, prenatal glucocorticoids induced changes in the T cell repertoire that resulted in more autoreactive cells. Even though glucocorticoids transiently enhanced regulatory T cell (Treg) development, these cells did not have a protective effect in a model for multiple sclerosis which relies on a limited repertoire of pathogenic T cells for disease induction that were not affected by prenatal betamethasone. We conclude that prenatal steroid treatment, by inducing changes in the T cell receptor repertoire, has unforeseeable consequences on development of autoimmune disease. Our data should encourage further research to fully understand the consequences of this widely used treatment.

Keywords: glucocorticoids, prenatal betamethasone, T cell repertoire, autoimmunity, type 1 diabetes, non-obese diabetic mice, experimental autoimmune encephalomyelitis mice, MRL/lpr

INTRODUCTION

Non communicable diseases (NCDs), such as cardiovascular diseases, diabetes, chronic respiratory diseases, and others, result from a combination of risk factors and are the leading cause for almost 70% of all deaths worldwide (1). Among these, autoimmune diseases are responsible for more than 5% deaths every year (2), and their incidence is steadily increasing (3, 4). Emerging
evidence suggests that prenatal and early life conditions, such as environmental exposure to pollutants, poor nutrition, stress, or medical interventions during pregnancy might act as pivotal determinants of NCD risk in later life (5). Fetal exposure to synthetic glucocorticoids, as consequence of antenatal corticosteroid (ACS) administration to the mother, constitutes a potentially amendable risk factor. ACS is the most important obstetric intervention available to reduce the occurrence and severity of respiratory distress syndrome and to improve the survival chances in premature infants (6). According to WHO recommendations, glucocorticoids (either betamethasone or dexamethasone) are given to mothers at risk of preterm birth between 24 and 34 weeks of gestation (7). The synthetic glucocorticoids cross the placenta and accelerate fetal lung maturation, achieving maximum benefit from 24 h to 7 days after administration (8). After injection, glucocorticoid bioactivity in the fetus lasts for several days (9) and can exert long-lasting effects upon the hypothalamic–pituitary–adrenal (HPA) axis and cognition in children (10, 11). Of note, 30–80% of women with symptoms of preterm birth have not delivered 14 days later (12), and more than half of the women who received ACS delivered later than one week after treatment or after 34 weeks of gestation (13), among them one third after gestation week 37 (14). Especially this population of neonates is likely to encounter more harm than benefits from the prenatal treatment with glucocorticoids.

Known as strong immune modulators, glucocorticoids act on a great variety of immune cells and have potent effects on the development of T lymphocytes. Exposure of developing thymocytes to glucocorticoids results in apoptotic death of the immature CD4+CD8+ double-positive (DP) subset (15), and we have previously shown that antenatal betamethasone treatment leads to a drastic decrease in the thymus volume and thymocyte numbers in the offspring (16). In order to sustain T cell output, the thymic niche is promptly replenished by newly imported hematogenous early thymic progenitors (17, 18), which will then proceed to the rearrangement of their T cell receptor (TCR) creating a highly diverse TCR repertoire and undergo positive and negative selection processes: thymocytes bearing non-functional TCRs or TCR with high affinity for self-peptide:MHC are deleted, while T cells with lower affinity TCRs mature and populate the periphery [reviewed in Ref. (19)]. However, even in healthy individuals, a number of autoreactive T cells escape this central tolerance checkpoint and migrate to the periphery, where peripheral tolerance mechanisms are engaged to prevent autoimmunity. Among these, thymic-derived Foxp3+ Treg cells and, in particular, a highly efficient population of Treg cells generated perinatally, are essential in preventing multiorgan autoimmune disease (20–23).

The delicate process of T cell repertoire selection may be compromised under altered glucocorticoid signaling (24–29), and as a consequence may have detrimental long-lasting effects on immunopathology and susceptibility to diseases. Therefore, we sought to investigate the influence of ACS treatment on the development of autoimmunity later in life. Using two mouse strains that spontaneously develop autoimmunity, namely the lupus-prone MRL/lpr strain and the non-obese diabetic (NOD) mouse, and the myelin oligodendrocyte glycoprotein (MOG)-induced mouse model for multiple sclerosis [experimental autoimmune encephalomyelitis (EAE)], we provide evidence that prenatal betamethasone treatment, by inducing changes in the T cell repertoire, can alter the course of autoimmune disease.

**MATERIALS AND METHODS**

**Mice and Treatment**

C57BL/6J, MRL/MpJ-Fas<sup>−/−</sup>/J, NOD mice (The Jackson Laboratory, Bar Harbor, ME, USA), and Foxp3<sup>RFP</sup> reporter mice (30), kindly provided by S. Huber, were housed and maintained under specific pathogen-free conditions. Mice were mated and the presence of a vaginal plug was considered day 0.5 of pregnancy (E0.5). On day 18.5 (E18.5) mice were treated by i.p. injection of 0.1 mg betamethasone (Sigma-Aldrich, Germany) in PBS or vehicle control (PBS). When indicated, 4- to 5-week-old animals were given 0.1 mg betamethasone i.p. or vehicle control (PBS) 24 h prior to organ harvesting. All animal experiments were performed in accordance with national and institutional guidelines on animal care and ethics.

**Flow Cytometry**

Thymi, lymph nodes and spleens were harvested and single-cell suspensions prepared by mechanical disruption and filtering through a 70 µm nylon mesh. Red blood cells were lysed when necessary and Fc receptors were blocked using anti-CD16/32 Abs prior to staining. Anti-mouse Abs used in this study were: anti-CD3e eFluor 450 (500A2), anti-CD4 APC-eFluor 780 (RM4-5) and anti-CD8α PE-Cy7 (53–6.7) from eBioscience (San Diego, CA, USA); anti-CD4 FITC (RM4-5), anti-CD4 BV421 (GK1.5), anti-CD8α PerCP-Cy5.5 (53–6.7), anti-CD25 PE (3C7), and anti-TCRβ chain PerCP-Cy5.5 (H57-597) from BioLegend (San Diego, CA, USA), and anti-CD3e FITC (145-2C11) from BD Biosciences (San Jose, CA, USA).

Analysis of TCR Vβ usage was performed using 15 FITC-conjugated monoclonal antibodies recognizing the TCR chains Vβ2, 3, 4, 5.1/5.2, 6, 7, 8.1/8.2, 8.3, 9, 10<sup>+</sup>, 11, 12, 13, 14, and 17<sup>+</sup> TCRs (BD Biosciences, San Jose, CA, USA). The percentage of Vβ<sup>+</sup> cells was determined in each subset after gating on CD4<sup>+</sup>, CD8<sup>+</sup>, and DN cells.

Data were collected on a Flow Cytometer (FacsCanto II, BD Biosciences, San Jose, CA, USA) and analyzed using FlowJo Software (Tree Star, Ashland, OR, USA). Cell sorting of thymocyte populations was performed on a FACS Aria IIIu (BD Biosciences, San Jose, CA, USA) carried out by the FACS sorting Core Unit of the University Medical Center Hamburg-Eppendorf.

**Thymocyte Sensitivity to Betamethasone**

One million thymocytes from 5-weeks-old untreated C57BL/6J mice were cultured in RPMI-1640 (Gibco, CA, USA) in a 96-well round bottom plate (Thermo Fisher Scientific, Germany) and incubated with increasing concentrations of betamethasone (0.1–100 nM) with or without the addition of 1 µg/ml mifepristone (RU486, Sigma-Aldrich). After 16 h at 37°C, cells were harvested, washed with 1× Annexin V Binding Buffer (Exbio,
PE-Cy7 antibodies. The proliferation of CD4 chain PerCPCy5.5, anti-CD4 APC-eFluor 780, and anti-CD8 stained with Dead Cell Stain-Pacific Orange and anti-TCR culture, lymph node cells were collected, washed with PBS and

Bethyl Laboratories, Inc. (45x419)
determined by ELISA (Mouse Albumin ELISA Quantitation Set; 2 h every 2 weeks starting at 6 weeks of age. Albuminuria was Mice were housed in metabolic cages for urine collection for

CA, USA). were analyzed using Prism software (GraphPad Software, La Jolla, CA, USA). a multilabel plate reader (Victor3, PerkinElmer, MA, USA), data were analyzed using Prism software (GraphPad Software, La Jolla, CA, USA).

Autologous Mixed Lymphocyte Reaction (AMLR)

Pooled single-cell suspensions from inguinal, axillary, brachial, lumbar, and superficial cervical lymph nodes were stained with the cell proliferation dye eFluor 670® (eBioscience, San Diego, CA, USA) in order to differentiate proliferating and non-proliferating cells. Shortly, lymph node cells were washed with PBS and resuspended in 2 µM eFluor 670® dye in PBS for 10 min at 37°C in the dark. Labeling was stopped by adding 4–5 volumes of cold complete medium (RPMI 1640, 10% FCS, 1% penicillin/streptomycin, 2 mM l-glutamine, 50 µM 2-Mercaptoethanol) and incubated on ice for 5 min. Labeled cells were then cultured in complete medium in the presence or absence of IL-2 (100 U/ml). Cells were plated at 1 × 10^5/ well in a 96-well plate (Thermo Fisher Scientific, Germany) for up to 5 days at 37°C in 5% CO₂. After 3, 4, and 5 days of culture, lymph node cells were collected, washed with PBS and stained with Dead Cell Stain-Pacific Orange and anti-TCRβ chain PerCPCy5.5, anti-CD4 APC-eFluor 780, and anti-CD8α PE-Cy7 antibodies. The proliferation of CD4⁺, CD8⁺, and DN cells was evaluated according to eFluor dilution measured by flow cytometry (FacsCanto II, BD Biosciences).

Disease Scoring

MRL/lpr Mice

Organ weights were measured and weight index (mg/g body weight) of lymphoid organs (spleen and lymph nodes) was calculated as follows: organ weight/body weight × 1,000.

Measurement of Double-Stranded (ds) DNA Autoantibodies

Blood samples were collected every 2 weeks of age and serum autoantibodies specific for dsDNA were measured by enzyme-linked immunosorbent assay (ELISA). 96-well plates were coated with 5 µg/ml calf thymus dsDNA (Sigma-Aldrich) at 4°C overnight. Plates were blocked for 2 h with 1% BSA in PBS followed by incubation with diluted mouse serum for 2 h at RT. Bound anti-dsDNA autoantibodies were detected with a 1:2,000 diluted sheep anti-mouse IgG-HRP (Amersham, UK) (2 h, RT), and peroxidase reaction was developed using 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (Sigma-Aldrich, Germany). Absorbance was measured at 405 nm using a multilabel plate reader (Victor3, PerkinElmer, MA, USA), data were analyzed using Prism software (GraphPad Software, La Jolla, CA, USA).

Measurement of Proteinuria

Mice were housed in metabolic cages for urine collection for 2 h every 2 weeks starting at 6 weeks of age. Albuminuria was determined by ELISA (Mouse Albumin ELISA Quantitation Set; Bethyl Laboratories, Inc.).

Non-Obese Diabetic (NOD) Mice

Starting at 10 weeks of age, adult mice were monitored daily for urine glucose using Glucocard strips (Menarini, Barcelona, Spain), until 25 weeks of age. Mice with glycosuria were confirmed diabetic when the blood glucose level was >300 mg/dl. The degree of immune cell infiltration in the islets (insulitis score) was determined at the end of the study in all non-diabetic mice. Briefly, pancreata were snap frozen in an isopentane/cold acetone bath. Cryosections of 5 µm were obtained at non-overlapping levels, stained with hematoxylin and eosin (H&E), and analyzed by two independent investigators in a blind fashion. A minimum of 40 islets per animal was analyzed. Insulitis was scored as described elsewhere (31): 0 = no insulitis; 1 = peri-insular inflammation; 2 = infiltration below 25%; 3 = infiltration 25–75%; 4 = infiltration above 75%.

EAE Mouse Model

For induction of EAE, C57BL/6J mice were immunized s.c. with 200 µg MOG₃₅–₅₅ peptide (Schafer-N, Copenhagen, Denmark) in complete Freund’s adjuvant (Difco Laboratories, LI, USA) containing 4 mg/mL Mycobacterium tuberculosis (Difco). In addition, 200 ng pertussis toxin (Calbiochem, San Diego, CA, USA) was injected i.v. on the day of immunization and 48 h later. Animals were scored daily for clinical signs by the following system: 0 = no clinical deficits; 1 = tail weakness; 2 = hind limb paresis; 3 = partial hind limb paralysis; 4 = full hind limb paralysis; 5 = forelimb paralysis; and 6 premorbid or dead. Animals reaching a clinical score ≥4 had to be killed according to the regulations of the Animal Welfare Act. Investigators were blinded for prenatal treatment during the experiments.

Gene Expression Analysis

RNA was extracted from sorted T cell subsets or from thymocytes after in vivo or in vitro treatment using the RNeasy Mini Plus kit (QIAGEN, Hilden, Germany) and cDNA was synthesized with the M-MLV Reverse Transkriptase kit (Invitrogen). TaqMan gene expression assay (LifeTechnologies, CA, USA) was used to detect GAPDH (Hs02758991_g1) expression. 18S and FoxP3 expression were determined using SYBR® green and following primers: 18S forward: 5′-GGGCTACCCACATCCAAAGGA-3′; 18S reverse: 5′-GCTGGAATTTACCGGGGT-3′; FoxP3 forward: 5′-GGCCCTTCTCCAGGGAGA-3′ FoxP3 reverse: 5′-GCTGATCATGGCTGGTTGT-3′.

Statistics

Statistical analysis of TCR Vβ chain usage was performed with Matlab R2016b (The Mathworks). The fractions of positive cells for each Vβ chain, as well as the remaining fraction of cells that was not positive for any of the measured Vβ chains (other Vβ), were log or square-root transformed to obtain normally distributed data. Using N-way ANOVA, the Vβ chain fractions for each cell type were correlated to treatment and possible interaction terms, with correction for litter size and subject nested within treatment. Upon reaching statistical significance, pairwise comparison with Fisher’s least significant difference correction was performed.
to identify which Vβ chain(s) were differently expressed upon treatment. For calling statistical significance, alpha of 0.05 was applied in all analyses.

Additional statistical analysis, including unpaired Student's t-test, Gehan–Breslow–Wilcoxon test, and Mantel–Cox test were performed with GraphPad Prism Software (La Jolla, CA, USA) and are indicated in the corresponding figure legends. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

Study Approval
This study was carried out in accordance with the recommendations of the Declaration of Helsinki for animal experimental investigation and the Principles of Laboratory Animal Care (NIH pub.85–23 revised 1985). The protocol was approved by the local animal ethics committees (ethical approval 119/13 and 122/12 obtained from the state authority of Hamburg, and DMAH8948 obtained from the Generalitat de Catalunya).

RESULTS

Prenatal Glucocorticoid Treatment Results in Apoptosis of DP Thymocytes in the MRL/lpr Offspring

We have previously shown in C57BL/6j mice that prenatal betamethasone treatment causes a profound reduction in the thymic volume and cell numbers in the offspring (16). The question that arises is if the massive death and subsequent accelerated replenishment of the thymus has consequences upon T cell repertoire selection and immunity later in life. To explore this, we took advantage of the MRL/MpJ-Fas lpr accelerated replenishment of the thymus has consequences that arise is if the massive death and subsequent thymic volume and cell numbers in the offspring (16). The MRL/lpr offspring in apoptosis of DP Thymocytes in the thymus of the offspring (16). The question that arises is if the massive death and subsequent accelerated replenishment of the thymus has consequences upon T cell repertoire selection and immunity later in life. To explore this, we took advantage of the MRL/MpJ-Fas lpr accelerated replenishment of the thymus has consequences upon T cell repertoire selection and immunity later in life.

To assess if prenatal glucocorticoid treatment had an effect on the autoimmune repertoire, we performed flow cytometric analysis of TCR Vβ chain usage in peripheral CD4+ and CD8- and DN T cells of young (5- to 7-week old) and aged (15- to 17-week old) offspring of mothers treated with vehicle or betamethasone. While the frequencies of CD4+, CD8-, and DN T cells at 5–7 weeks of age, before appearance of disease symptoms, were similar in both groups, accumulation of DN T cells in the older animals was clearly more prominent in the group that had received betamethasone prenatally (Figures 2A,B). Moreover, analysis of Vβ chain usage on the different T cell subsets indicated a bias in TCR receptor Vβ expression in these mice, with higher representation of the potentially autoreactive Vβ2- (7.97 vs. 8.95%, P = 0.0564), Vβ8.1/8.2- (10.91 vs. 12.85%, P = 0.0379), and Vβ10- (1.97 vs. 2.85%, P = 0.0113) expressing DN T-cells in young animals (5–7 weeks) (Figures 2C,E) and further differences in the frequency of Vβ5.1 CD4+ and CD8- cells, Vβ11 in CD4+ T cells, and Vβ12 in CD44+ T and DN T cells (Table S1 in Supplementary Material). Similarly, the TCR Vβ usage in MRL/lpr animals with advanced disease (at 15–17 weeks of age) was also biased, with differences in the frequency of Vβ14 (7.46 vs. 8.46%, P = 0.0114) CD8- T cells and, as in young animals, in the disease-relevant Vβ10- (4.78 vs. 6.18%, P = 0.0389) bearing DN cells (Figures 2D,F; Table S2 in Supplementary Material).

We next sought to determine whether the changes observed in the TCR Vβ repertoire resulted in a higher proliferation, which would reflect the presence of more autoreactive cells. For this, we performed AMLR to measure proliferation of autoreactive T cells in response to endogenous antigens. While no external TCR stimulus was given, IL-2 was added to the cultures to support the incipient proliferation of the few autoreactive precursors. Although not significant, our data show higher proliferation rates of both CD4+ and CD8- cells in the betamethasone-exposed animals (Figure 2G). As expected, DN cells showed maximal proliferation, and no differences were found between the treated and non-treated groups, since the accumulating DN cells are chronically activated in both groups.
The lpr defect in this mouse strain leads to a progressive enlargement of the lymphoid organs, enhancing the disease phenotype of the MRL strain (33). Therefore, we would expect that a T cell repertoire biased toward more autoreactivity would result in larger lymphoid organs. In agreement with increased amounts of pathogenic TCR Vβ families and enhanced T cell proliferation, the spleens and lymph nodes were considerably larger in the animals whose mothers had been treated with betamethasone (Figures 2H,I), supporting the concept of a more autoreactive T cell repertoire. However, a higher frequency of autoreactive T cells and enlarged lymphoid organs did not translate in accelerated course of disease, as assessed by the levels of dsDNA autoantibodies (Figure 2J) and proteinuria (Figure S1 in Supplementary Material) from 6 to 16 weeks of age, which were similar in both groups. Of note, prenatal betamethasone treatment resulted in a transiently lower body weight (Figure 2K) and higher production (Figures 2H,I), supporting the concept of a more autoreactive T cell repertoire.
Figure 2 | Continued
of ds-DNA specific IgG autoantibodies (Figure 2) at 6 weeks of age, but this difference disappeared soon after. Thus, prenatal treatment of the pregnant females with betamethasone elicits dramatic thymocyte death in the postnatal thymus, which results in persistent changes in the TCR repertoire promoting the expansion of autoreactive Vβ families.

Prenatal Betamethasone Protects from T1D Development in NOD Mice

Despite the critical role of T cells in the initiation of autoimmunity in MRL/lpr mice, other mechanisms such as the production of pathogenic autoantibodies and renal immune-complex deposition leading to complement activation, contribute fundamentally to disease progression. Therefore, we turned to a second model of autoimmunity with a more direct involvement of T cells in the immune pathogenesis, the NOD mouse model for T1D to assess persisting effects of prenatal betamethasone treatment. This spontaneous model of autoimmune diabetes is characterized by the activation of autoreactive T cells and the destruction of insulin producing beta-cells in the pancreas. After prenatal administration of vehicle or betamethasone to non-diabetic females (E 18.5), glucose levels were measured in the female offspring for the occurrence of T1D until 25 weeks of age (Figure 3A). Surprisingly, we found that fetal glucocorticoid exposure was protective against the development of T1D in females (Figure 3B). At 25 weeks of age, only 25% of the NOD females in the control group were disease-free, while in the betamethasone treatment group it was 78%. Moreover, T1D onset was delayed in the treated group (from 14 weeks of age) when compared to control mice (from 11 weeks of age), consistently with the protective effect of the drug. There were no differences between the two groups in the frequencies of CD4+, Treg cells, CD8+, or CD3+ DN spleen cells at 6 weeks of age (Figure 3C). We next investigated whether the different incidence of disease could be traced to changes in the TCR Vβ repertoire. In the NOD mice, the most commonly found TCR Vβ chains in T cells infiltrating the pancreas are Vβ4 (37), and Vβ12 (38, 39), followed by Vβ8.1, Vβ2, and Vβ6 (40, 41). Our TCR Vβ usage analysis revealed that Vβ12 (6.71 vs. 5.45%, P = 0.0077) CD4+ T cells, and Vβ4 (2.66 vs. 2.14%, P = 0.0683) and Vβ6 (9.28 vs. 7.39%, P = 0.0124) CD8+ T cells were underrepresented in the spleen of the female NOD mice whose mothers received betamethasone (Figures 3D,E; Table S3 in Supplementary Material). This lower frequency of pathogenic TCRs was reflected in the lower degree of immune cell infiltration in the pancreas of animals that had not yet developed T1D at 25 weeks of age, determined in a second mouse cohort (Figures 3F–H). Here, the incidence was somewhat lower in both groups, but still 46% of sham-treated females were disease-free at 25 weeks, while 62% of the betamethasone-treated had normal glucose levels (P = 0.0847, Figure S2 in Supplementary Material). Therefore, we conclude that a bias in the T cell repertoire caused by prenatal glucocorticoid treatment contributes to protection from T1D in the NOD mice.

Prenatal Betamethasone Does Not Induce Long Lasting Changes in the Treg Cell Compartment

In addition to changes in TCR Vβ usage, another possibility that could affect development of autoimmunity is the quantity or quality of Treg cells. Treg cells are less sensitive to glucocorticoid challenge than conventional CD4+ cells (42, 43). However, it is not known if prenatal treatment with betamethasone results in enrichment of Treg cells in the newborn and, more importantly, if there are consequences for the peripheral Treg cell compartment later in life. In a first set of experiments we exposed thymocytes from 6 weeks old (not prenatally treated) C57BL/6J mice to increasing concentrations (0.1–100 nM) of betamethasone in vitro and measured the survival of Treg cells compared to conventional CD4+ T cells. We used mifepristone (RU486), a synthetic steroid with potent anti-glucocorticoid properties, to confirm the specificity of the betamethasone effects. We found that the relative frequency of surviving CD4+CD25+SP thymocytes (which in naive mice are considered Treg cells) increased in response to betamethasone in a dose-dependent manner, and this effect was completely inhibited by the addition of RU486 (Figure 4A). More than a threefold increase in the frequency of Treg cells compared to the untreated controls was achieved at 10 nM (Figure 4A). In contrast, conventional CD4+ single-positive thymocytes did not significantly change in proportion with increasing concentrations of betamethasone (Figure 4B). To confirm that it is indeed
**Figure 3** Prenatal steroid treatment reduces insulitis and the incidence of T1D in NOD mice. (A) Schematic representation of the NOD mouse model. (B) Percentage of T1D-free NOD mice during 25 weeks of follow-up (n = 16–18 females per group). Gehan–Breslow–Wilcoxon test was used for statistical analysis. (C) Frequency of CD4⁺, Treg cells, CD8⁺, and DN splenocytes from female NOD mice at 6 weeks (n = 9–12 per group). (D) Comparison of Vβ chain usage between NOD offspring from betamethasone- (Bet) and sham-treated (PBS) dams at 6 weeks of age (n = 9–12 per group, female). Each T cell receptor (TCR) Vβ chain among CD4⁺ and CD8⁺ T cells is represented by a segment proportional in size to its frequency (which on average cover between 55 and 78% of all cells within the T cell subsets, the segment “other Vβ” indicates Vβ chain expression not covered by our panel of TCR Vβ chain-specific Abs). Segments marked with a star differ statistically significant between the groups (PBS or Bet), framed segments indicate TCR Vβ chains important for autoimmune disease in NOD mice. (E) Detailed results for the relevant TCR Vβ12 in CD4⁺ and TCR Vβ4 and Vβ6 in CD8⁺ spleen cells. N-way ANOVA was used for statistical analysis of TCR Vβ chain usage. (F) Representative H&E stained sections of pancreata from male and female T1D-free mice at sacrifice (25 weeks). (G) Insulitis score and (H) percentage of islets infiltrated from non-diabetic male and female (n = 3 per group) NOD mice. Unpaired Student’s t-test was used for statistical analysis, *P < 0.05 and **P < 0.01.
the Treg cell subset the one increasing, we performed RT-PCR on the cultured cells and found increased Foxp3 expression at higher betamethasone concentration (Figure 4C). We obtained similar results when thymocytes derived from untreated Foxp3RFP reporter mice were treated with betamethasone and Foxp3 expression could be monitored by flow cytometry (Figure S3 in Supplementary Material). To test the effects of glucocorticoids on the frequency of Treg cells in vivo, we treated 6 weeks old mice i.p. with 0.1 mg betamethasone. Analysis of the thymus 24 h post-treatment revealed a net increase in CD4+CD25+ in the surviving cells (Figure 4D). Finally, to find out if prenatal betamethasone exposure has an effect on the frequency of neonatal Treg cells, we treated pregnant females and analyzed Treg precursor cells in the DP thymocytes and in the CD4SP subpopulations in the offspring at postnatal day 0. As shown in Figure 4E, we could detect an increased frequency of CD4+CD25+ thymic-derived Treg cells 24 h post-treatment (Figure 4F). This neonatal bias, however, did not persist until adulthood, since the percentage of Treg cells in the spleen of animals at 5–7 weeks of age was similar in both groups (Figure 4G). Moreover, no differences were observed in the expression of neuropilin-1 (Figure 4H) or CD62L (not shown), indicating similar percentages of thymic and peripherally induced Treg cells (44), and similar levels of activation in both groups. Proliferation and inflammatory cytokine production of spleen T cells at this age was also comparable in both groups (not shown). Our data demonstrate that Treg thymocyte precursor cells are less sensitive than conventional CD4+ precursors to prenatal administration of betamethasone, resulting in a transient increase in the frequency of Treg precursor cells after birth. However, these differences are not persisting, and do not elicit changes in the future Treg cell compartment.

**Prenatal Betamethasone Has No Effect on Disease in the Context of a Highly Restricted Pathogenic Repertoire**

In the two models of autoimmune disease that we have analyzed, disease develops spontaneously, and the TCR repertoire of the pathogenic cells is oligoclonal. In both cases, we have shown that antenatal betamethasone treatment elicits changes in the TCR Vβ usage affecting the autoreactive T cell repertoire. To address if indeed glucocorticoid-induced changes in the TCR repertoire are responsible for this effect, we took advantage of a model in which only few TCRs are engaged in the pathogenic response, namely EAE induced by MOG35–55 peptide. In contrast to the more polyclonal response in the lupus-prone MRL/lpr mouse and in the NOD mouse model, in this induced model of autoimmunity, half of the CNS infiltrating cells bear Vβ8.1 or Vβ8.2 (45–47). We therefore treated pregnant C57BL/6J females with betamethasone at E18.5, and let the offspring develop normally, until injection of the MOG peptide at 6 weeks of age (Figure 5A). After disease induction, mice were examined daily and scored for clinical symptoms of disease for 30 days.
Figure 5 | Prenatal betamethasone does not alter the onset or the course of experimental autoimmune encephalomyelitis (EAE) despite changes in the T cell receptor (TCR) Vβ repertoire. (A) Schematic representation of the EAE mouse model. (B) EAE clinical scores and (C) survival of C57BL/6J mice (n = 9–11 per group, male and female) after MOG35–55 EAE induction in offspring of dams prenatally treated with betamethasone or PBS. Statistical analysis of survival was performed with Mantel–Cox test. (D) Comparison of Vβ chain usage between C57BL/6J offspring from betamethasone- or sham-treated mothers. Each TCR Vβ chain among CD4+ and CD8+ splenocytes is represented by a segment proportional in size to its frequency (which on average cover between 74 and 84% of all cells within the T cell subsets, the segment “other Vβ” indicates Vβ chain expression not covered by our panel of TCR Vβ chain-specific Abs). Segments marked with a star differ statistically significant between the groups (PBS or Bet), framed segments indicate TCR Vβ chains important for autoimmune disease in EAE mice. Data obtained at 5–7 weeks (n = 15 per group, male and female). (E) TCR Vβ chain usage represented as percent of change to negative control (PBS) ± SEM. N-way ANOVA was used for statistical analysis of TCR Vβ chain usage, *P < 0.05, **P < 0.01, and ***P < 0.001.
No differences could be seen in disease onset, clinical score or survival between the animals whose mothers had been treated with betamethasone or with vehicle (Figures 5B,C). Analysis of the TCR repertoire revealed significant changes in Vβ chain usage between the two groups, namely affecting Vβ5.1/5.2 (2.73 vs. 3.27%, \( P = 0.0004 \)) and Vβ7 (2.24 vs. 1.99%, \( P = 0.0315 \)) in CD4+ and Vβ7 (5.79 vs. 5.22%, \( P = 0.0040 \)) in CD8+ T cells. However, the frequency of the disease-relevant Vβ8.1/8.2 chains remained unchanged (Figures 5D,E; Table S4 in Supplementary Material). Our data show that prenatal betamethasone is not altering the highly restricted pathogenic TCR repertoire in EAE, and—consequently—the disease course is similar in both groups of mice.

**DISCUSSION**

Glucocorticoids are administered to pregnant women at risk of preterm delivery. A single course of betamethasone reduces morbidity related to acute respiratory distress in the neonate, without apparent short-term side effects (6). However, a complete absence of a thymic shadow in X-ray images has been reported for all newborns that received prenatal dexamethasone treatment, while in the majority of healthy gestation-week matched untreated controls the thymus was visible (48). This condition is transient, since control X-rays over the first 4 weeks of life showed a progressive enlargement of the thymic gland (48). To explore possible long-term consequences of prenatal glucocorticoids in humans is a challenge, since women are treated upon symptoms of pre-term birth, which may happen at different time points of pregnancy, and the time span between treatment and birth can also be highly variable. It is therefore not surprising that analysis of cord blood parameters has not yielded conclusive results [reviewed in Ref. (49)]. Interestingly, epidemiological studies in much larger cohorts indicate an increased risk for infection in the neonate (50), and for asthma (51) and T1D (52) in young children that received prenatal steroid treatment.

For the reasons mentioned above in relation to human studies, we decided to use mouse models to explore possible long-term consequences of prenatal steroids upon the immune system. One dose of betamethasone equivalent to what is given in human pregnancy was injected to the dams before delivery. This dose is the minimum dose that showed improved lung maturation compared to vehicle in mice (53). Our experiments showed a drastic reduction in thymic size and cell numbers after prenatal betamethasone in the three mouse strains tested. The thymus plays an essential role for the development of a functional and self-tolerant TCR repertoire. Positive and negative selection events based on TCR avidity for self pMHC, ensure the elimination of non-functional or autoreactive T cells. Glucocorticoids have been shown to regulate the avidity threshold between positive and negative selection, and altered glucocorticoid signaling results in a biased T cell repertoire (26–28, 54, 55). Thus, it is plausible that an excess of glucocorticoids in a moment of active immune development, like the perinatal period, causes changes in the T cell repertoire influencing development of autoimmunity.

Autoreactive T cell clones bearing distinct TCR Vβ chains expand in the target organs of autoimmune disease. For instance, T cells of the Vβ8.2 family recognizing MOG\(_{35-55}\) are predominant in the brain of C57BL/6 mice (47), and the repertoire of T cells infiltrating the pancreas of the NOD mouse is skewed to a limited set of families, including Vβ2, Vβ4, Vβ6, Vβ8.1, and Vβ12 (37–41, 56). Interestingly, injection of dexamethasone in the first 3 days of life has been shown to exert long-lasting effects on the expression of several Vβ genes in rats (57). We thus sought to assess the effect of prenatal corticosteroid treatment on the TCR Vβ repertoire in two spontaneous mouse models of autoimmunity. We decided to use flow cytometry to assess TCR Vβ family usage because it allows efficient measurement on the different T cell subsets in individual mice simultaneously, without previous cell sorting. Exploiting this strategy, we observed that Vβ chains that are relevant for the development of T1D in the NOD mouse are underrepresented in the offspring of mothers that were treated with betamethasone. For instance, we found decreased frequencies of peripheral T cells bearing the Vβ4 in mice whose mothers received betamethasone. Vβ4 is utilized by all NOD mice in response to a dominant epitope on glutamic acid decarboxylase 65, and T cell responses to this antigen are already detected in the spleens of young pre-diabetic NOD mice (37), suggesting that this is an important epitope of the primary response. The oligoclonal pattern of islet infiltrating T cells in the NOD model in pre-diabetic mice (40, 41) is a strong indication of local antigen-driven expansion of a limited number of clonotypes, at least at the start of the disease, before epitope spreading. Thus, even subtle changes in the composition of the TCR repertoire, if affecting the relevant specificities, are likely to influence disease development. Not surprisingly, disease severity remained unchanged after prenatal betamethasone treatment in MOG-induced EAE, where T cells from the TCR Vβ8.1/8.2 families, which account for half of the cells infiltrating the central nervous system (46), were not affected by prenatal steroid treatment.

In contrast to the NOD model, we found that Vβ chains known to be expanded in the lymph nodes of MRL/lpr mice are more prominent in the offspring of betamethasone-treated mothers. In this particular mouse strain, the defect in Foxp3 gene promotes the accumulation of activated autoreactive cells with the CD3+CD4−CD8− DN phenotype in peripheral lymphoid organs (33, 58). The expanded population of the abnormally proliferating lymph node T cells in MRL/lpr mice is heterogeneous, but Vβ gene expression is skewed toward members of the Vβ2 and Vβ8 families in the DN population (35, 36, 59, 60). The pathogenic nature of Vβ8-bearing T cells is underpinned by the lack of disease in animals that have been treated with anti-TCR Vβ8 antibodies (61). Our data show that Vβ2, Vβ8.1/8.2 and Vβ10 are overrepresented in the DN population in the offspring of betamethasone-treated mothers, indicating a larger contingent of autoreactive cells in these animals. This is further supported by the higher proliferation of CD4+ and CD8+ T cells in the AMLR, and the larger size of lymphoid organs. Still, we did not observe more severe disease in the treated animals, which is probably due to the fact that although autoreactive T cells contribute to the initiation of disease, the underlying causes for the pathogenesis...
in the MRL/lpr lupus model lie in the activation of complement by immune complex deposition in the kidney and blood vessels, and inflammatory responses triggered by defects in the clearance of dying cells (62, 63).

How do prenatal glucocorticoids exert their effect on the T cell repertoire? Using different strategies of glucocorticoid-receptor deficiency it has already been shown that diminished glucocorticoid signaling can alter the positive and negative selection avidity thresholds, or create “holes” in the TCR repertoire (26–28). Indeed, lymph nodes and spleen were smaller and the TCR repertoire was less autoreactive in MRL/lpr animals with deficient glucocorticoid receptor expression in thymocytes (26), which is the opposite effect of what we have observed after prenatal excess of glucocorticoids. Mechanistically, this could be due to the ability of glucocorticoids to regulate T cell activation-related processes, thus influencing the outcome of thymic selection. Another possibility is that glucocorticoids alter the TCR repertoire by modulating the transcription of endogenous retroviruses encoding for superantigens (64). Steroid hormones stimulate the expression of HERV-K in human cell lines (65), and a recent study has shown that all endogenous retroviral promoters tested responded to dexamethasone treatment with changes in activity in more than 20 mouse strains (66). Since in the process of developing tolerance to superantigens the TCR-reactive Vβ chains are partially or completely deleted in the thymus (67), glucocorticoid-induced changes in the transcription of endogenous retroviruses could be the underlying cause for the differences that we find in the peripheral TCR repertoire. Indeed, endogenous retroviral sequences induced autoreactive T cells when injected into neonate NOD, but not C57BL/6 mice (68), highlighting the importance of this pathway for the modulation of the T cell repertoire, but also the strain-specific effects (66, 69). In humans, reactivation of endogenous retroviruses has been associated to several autoimmune diseases, including T1D, multiple sclerosis and systemic lupus erythematosus [reviewed in Ref. (70)]. For instance, viral particles of the human endogenous retrovirus HERV-K have been isolated from pancreatic islets of T1D patients, suggesting a possible role of glucocorticoids to regulate T cell activation-related processes, thus influencing the outcome of thymic selection. Another possibility is that glucocorticoids alter the TCR repertoire by modulating the transcription of endogenous retroviruses encoding for superantigens (64).

A limitation of our prenatal betamethasone treatment model is that not all fetuses are equally affected by prenatal steroid treatment [Figure 1D (16)]. At the time point PND1, the relative frequencies of CD4+CD8+ thymocytes or of granulocytes in spleen can be taken as a proxy for the amount of betamethasone that the fetus received. At 6 weeks of life, however, it is not possible to identify the animals that were only minimally affected, and this will not be the case in human singleton pregnancies. A possibility to overcome this problem in the mouse model could be to inject betamethasone postnatally, however, the influence of the incoming microbiome will probably mask the effects of betamethasone. Finally, while our data clearly demonstrate that changes in the TCR repertoire alter the course of autoimmunity, additional T cell-independent mechanisms influencing the outcome of disease are not ruled out.
In this study, we asked whether prenatal exposure to glucocorticoids influences the development of autoimmunity later in life. By analyzing TCR Vβ usage in two mouse strains that spontaneously develop autoimmunity and in the MOG-EAE model, we provide evidence that prenatal betamethasone treatment, by changing the peripheral T cell repertoire, modifies the autoreactive T cell pool, and this may lead to unpredictable variations in the course of autoimmune disease, depending on which T cell clonotypes are affected. Thus, in spite of the undisputable benefits of prenatal glucocorticoids for infants born prematurely, this treatment may be associated with long-term effects on immunity, and it should be used with caution in cases where the risk of preterm birth is only marginal.

ETHICS STATEMENT

This study was carried out in accordance with the recommendations of the Declaration of Helsinki for animal experimental investigation and the Principles of Laboratory Animal Care (NIH pub.85–23 revised 1985). The protocol was approved by the local animal ethics committees (ethical approval 119/13 and 122/12 obtained from the state authority of Hamburg, and DMAH8948 obtained from the Generalitat de Catalunya).

AUTHOR CONTRIBUTIONS

AG, CG, ID, and ET designed the experiments. AG, CG, DP-B, JE, ID, NK, and SK performed experiments and acquired data. AG, CG, DP-B, JE, and ID analyzed data and interpreted results. AG and SJ performed statistical analyses. LG conducted data visualization. AG and LG prepared the final figures. H-WM, MF, and MV made intellectual contributions. AG and ET wrote the manuscript. All authors read the manuscript and approved submission.

ACKNOWLEDGMENTS

We thank S. Huber (Center for Internal Medicine, UKE) for kindly providing Foxp3mRFP reporter mice and the UKE Flow Cytometry Core Facility for help in sorting. We further thank Manuela Kolster and Romy Hackbusch for excellent technical help and Sabrina Noster for animal husbandry. We thank Mr. M. Fernandez (Germans Trias I Pujol Research Institute) for technical assistance with flow cytometry.

FUNDING

This work was supported by the Deutsche Forschungsgemeinschaft (KFO296) and a Promotionstipendium der Studienstiftung des deutschen Volkes.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at http://www.frontiersin.org/article/10.3389/fimmu.2017.01505/full#supplementary-material.

REFERENCES

1. WHO. Global Status Report on Noncommunicable Diseases 2014. Geneva: WHO (2014).
2. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med (2015) 278(4):369–95. doi:10.1111/joim.12395
3. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med (2002) 347(12):911–20. doi:10.1056/NEJMoa0210010
4. Kondrashova A, Seiskari T, Ilenon J, Knip M, Hyoty H. The ‘hygiene hypothesis’ and the sharp gradient in the incidence of autoimmunity and allergic diseases between Russian Karelia and Finland. APMIS (2013) 121(6):478–93. doi:10.1111/apm.12023
5. Eriksson JG. Developmental origins of health and disease – from a small body size at birth to epigenetics. Ann Med (2016) 48(6):456–67. doi:10.1080/07853890.2016.1193786
6. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev (2006) (3):CD004454. doi:10.1002/14651858.CD004454.pub2
7. WHO. Improving Preterm Birth Outcomes. Execute Summary. Geneva: WHO (2015).
8. Vidaeff AC, Belfort MA, Steer PJ. Antenatal corticosteroids: a time for more careful scrutiny of the indications? BJOG (2016) 123(7):1067–9. doi:10.1111/1471-0528.13853
9. Kajantie E, Raivio T, Janne OA, Hovi P, Dunkel L, Andersson S. Circulating glucocorticoid bioactivity in the preterm newborn after antenatal betamethasone treatment. J Clin Endocrinol Metab (2016) 101(2):581–9. doi:10.1210/jc.2015-2453
10. Alexander N, Rosenlocher F, Stalder T, Linke J, Distler W, Morgner J, et al. Impact of antenatal synthetic glucocorticoid exposure on endocrine stress reactivity in term-born children. J Clin Endocrinol Metab (2012) 97(10):3538–44. doi:10.1210/jc.2012-1970
11. Whitworth MK. Recent guidance on antenatal corticosteroids in prematurity. BJMF (2016) 352:i1655. doi:10.1136/bmj.i1655
12. Davidson C, Monga M, Ellison D, Vidaeff A. Continuation of pregnancy after antenatal corticosteroid administration: opportunity for rescue? J Reprod Med (2010) 55(1–2):14–8.
13. Pereira L, Caughey AB. Predicting preterm birth: where do the major challenges lie? J Perinatol (2012) 32(7):481–2. doi:10.1038/jp.2012.54
14. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature (1980) 284(5756):555–6. doi:10.1038/284555a0
15. Diepenbruck I, Much CC, Krummbholz A, Kolster M, Thieme R, Thieme D, et al. Effect of prenatal steroid treatment on the developing immune system. J Mol Med (Berl) (2013) 91(11):1293–302. doi:10.1007/s00109-013-1069-2
16. Enslenkoy E, Goldschnieder I. Thymocytes are maintained by blood-borne precursors throughout postnatal life. A study in parabiotic mice. J Immunol (1992) 148(6):1604–12.
17. Penit C, Vasseur F. Cell proliferation and differentiation in the fetal and early postnatal mouse thymus. J Immunol (1989) 142(10):3369–77.
18. Kurd N, Robey EA. T-cell selection in the thymus: a spatial and temporal perspective. Immunol Rev (2016) 271(1):114–26. doi:10.1111/imr.12398
19. Hsieh CS, Lee HM, Lio CW. Selection of regulatory T cells in the thymus. Nat Rev Immunol (2012) 12(3):157–67. doi:10.1038/nri3155
20. Sakaguchi S, Sakaguchi N, Asano M, Ohh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 155(3):1151–64.
21. Yang S, Fujikado N, Kolodin D, Benoist C, Mathis D. Immune tolerance. Regulatory T cells generated early in life play a distinct role in maintaining
self-tolerance. Science (2015) 348(6234):589–94. doi:10.1126/science.aaa7017
23. Chen K, Benoit C, Mathis D. How defects in central tolerance impinge on a deficiency in regulatory T cells. Proc Natl Acad Sci U S A (2005) 102(41):14735–40. doi:10.1073/pnas.050710141
24. Vaccio MS, Ashwell JD. Thymus-derived glucocorticoids regulate antigen-specific positive selection. J Exp Med (1997) 185(11):2033–8. doi:10.1084/jem.185.11.2033
25. King LB, Vaccio MS, Dixon K, Hunziker R, Margulies DH, Ashwell JD. A targeted glucocorticoid receptor antisense transgene increases thymocyte apoptosis and alters thymocyte development. Immunity (1995) 3(5):647–56. doi:10.1016/1074-7613(95)90135-3
26. Tolosa E, King LB, Ashwell JD. Thymocyte glucocorticoid resistance alters positive selection and inhibits autoimmunity and lymphoproliferative disease in MRL-1pr/lpr mice. Immunology (1998) 8(1):67–76. doi:10.1046/s1074-7613.0080459-8
27. Lu FW, Yasutomo K, Goodman GB, McHeyzer-Williams LJ, McHeyzer-Williams MG, Germain RN, et al. Thymocyte resistance to glucocorticoids leads to antigen-specific unresponsiveness due to “holes” in the T cell repertoire. Immunity (2000) 12(2):183–92. doi:10.1016/S1074-7613(00)80171-5
28. Mittelstadt PR, Monteiro JP, Ashwell JD. Thymocyte responsiveness to endogenous glucocorticoids is required for immunological fitness. J Clin Invest (2004) 113(8):824–9. doi:10.1172/JCI26667
29. Wiegers GI, Kaufmann M, Tischer D, Villunger A. Shaping the T cell repertoire: a matter of life and death. Immunol Cell Biol (2011) 89(1):33–9. doi:10.1038/icb.2010.127
30. Wan YY, Flavell RA. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci U S A (2005) 102(14):5126–31. doi:10.1073/pnas.0501701102
31. Alba A, Puertas MC, Carrillo J, Planas R, Ampudia R, Pastor X, et al. IFN beta accelerates autoimmune type 1 diabetes in nonobese diabetic mice and breaks the tolerance to beta cells in nondiabetes–prone mice. J Immunol (2004) 173(1):6667–75. doi:10.4049/jimmunol.173.11.6667
32. Nose M, Nishihara M, Fujii H. Genetic basis of the complex pathological manifestations of collagen disease: lessons from MRL/lpr and related mouse models. J Exp Med (2004) 199(1):4–57. doi:10.1080/0724499090555081
33. Watanabe-Fukunaga R, Branncil CL, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature (1992) 356(6367):314–7. doi:10.1038/356314a0
34. Mountz JD, Smith TM, Toth KS. Altered expression of self-reactive T cell receptor V beta regions in autoimmune mice. J Immunol (1990) 144(6):2159–66.
35. Senger PA, McEvilly RJ, Noonan DJ, Dixon FJ, Theofilopoulos AN. Clonal diversity and T-cell receptor beta-chain variable gene expression in enlarged lymph nodes of MRL-1pr/lpr lupus mice. J Immunol (1986) 138(18):7018–22. doi:10.4049/jimmunol.138.18.7018
36. Zhou G, Fujio K, Sadakata A, Okamoto A, Yu R, Yamamoto K. Identification of systemically expanded activated T cell clones in MRL-1pr/lpr and NZB/W F1 lupus model mice. Clin Exp Immunol (2004) 136(3):448–55. doi:10.1111/j.1365-2249.2004.02473.x
37. Quinn A, McNerney M, Huffman D, McNerney MY, Mayo S, Haskins K, et al. T cells to a dominant epitope of GAD65 express a public CDR3 motif. Int Immunol (2006) 18(6):967–79. doi:10.1093/intimm/ddi033
38. Sarukhan A, Gombert JM, Olivi M, Bach JF, Carnaud C, Garchon HJ. Anchored polymerase chain reaction based analysis of the V beta repertoire in the core epitope encephalitogenic for T cell receptor V beta b and T cell receptor V beta lpr/lpr mice. Immunology (1994) 24(8):1750–6. doi:10.1111/j.1365-2141.1994.tb05811.x
39. Diz R, Garland A, Vincent BG, Johnson MC, Spidale N, Wang B, et al. Autoeffective reector/memory CD4+ and CD8+ T cells infiltrating grafted and endogenous islets in diabetic NOD mice exhibit similar T cell receptor usage. PLoS One (2012) 7(12):e50254. doi:10.1371/journal.pone.0050254
40. Marrero I, Aguilera C, Hamm DE, Quinn A, Kumar V. High-throughput sequencing reveals restricted TCR Vbeta usage and public TCRbeta clonotypes among pancreatic lymph node memory CD4(+) T cells and their involvement in autoimmune diabetes. Mol Immunol (2016) 74:82–95. doi:10.1016/j.molimm.2016.04.013
41. Bakker JM, Kavelaars A, Kamphuis PJ, Zijlstra J, van Bel F, Heerijen CJ. Neonatal dexamethasone treatment induces long-lasting changes in T-cell receptor Vbeta repertoire in rats. J Neuroimmunol (2001) 112(1–2):47–54. doi:10.1016/S0165-5728(00)00406-9
42. Martina MN, Noel S, Saxena A, Rabb H, Hamad AR. Double negative (DN) alphabeta T cells: misperception and overdue recognition. Immunol Cell Biol (2015) 93(3):305–10. doi:10.1038/icb.2014.99
59. Herron LR, Eisenberg RA, Roper E, Kakkanaiha VN, Cohen PL, Kotzin BL. Selection of the T cell receptor repertoire in lpr mice. J Immunol (1993) 151(3):1218–24.

60. Maldonado MA, Kakkanaiha V, MacDonald GC, Chen F, Reap EA, Balish E, et al. The role of environmental antigens in the spontaneous development of autoimmune in MRL/lpr mice. J Immunol (1999) 162(11):6322–30.

61. De Alboran IM, Gutierrez JC, Gonzalo JA, Andreu JL, Marcos MA, Kroemer H, et al. Defects in lysosomal maturation facilitate the activation of innate sensors in systemic lupus erythematosus. Proc Natl Acad Sci U S A (2016) 113(15):E2142–51. doi:10.1073/pnas.1513943113

62. Monteith AJ, Kang S, Scott E, Hillman K, Rajfur Z, Jacobson K, et al. Defects in endogenous retrovirus-K promoter: a landing strip for inflammatory transcription factors? J Immunol (2002) 169(5):2989–98. doi:10.4049/jimmunol.169.5.2989

63. Potter PK, Cortes-Hernandez J, Quertier P, Botto M, Walport MJ. Lupus-prone mice have an abnormal response to thioglycolate and an impaired clearance of apoptotic cells. J Immunol (2003) 170(6):3223–32. doi:10.4049/jimmunol.170.6.3223

64. Manghera M, Douville RN. Endogenous retrovirus-K promoter: a landing strip for inflammatory transcription factors? Retrovirology (2013) 10:16. doi:10.1186/1742-4690-10-16

65. Ono M, Kawakami M, Ushikubo H. Stimulation of expression of the human endogenous retrovirus genome by female steroid hormones in human breast cancer cell line T47D. J Virol (1987) 61(6):2059–62.

66. Hsu K, Lee YK, Chew A, Chiu S, Lim D, Greenhalgh DG, et al. Inherently clearances of apoptotic cells. J Biomed Res Int (2016) doi:10.1155/2016/9409452

67. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell (2014) 157(12):1–41. doi:10.1016/j.cell.2014.03.011

68. Cortese R, Lu L, Yu Y, Ruden D, Clau E. Epigenome-microbiome crosstalk: a potential new paradigm influencing neonatal susceptibility to disease. Epigenetics (2016) 11(3):205–15. doi:10.1080/15592294.2016.1155011

69. Das MR, Cohen A, Zamvil SS, Offner H, Kuchroo VK. Prior exposure to an agonist self-peptide. J Immunol (2001) 167(3):1404–10. doi:10.4049/jimmunol.167.3.1404

70. Balada E, Vilardell-Tarres M, Ordi-Ros J. Implication of human endogenous retroviruses in the development of autoimmune diseases. Int Rev Immunol (2010) 29(4):351–70. doi:10.1080/08830185.2010.485333

71. Conrad B, Weissmahr RN, Boni J, Arcari R, Schupbach J, Mach B. A human endogenous retroviral superantigen as candidate autoimmune gene in type 1 diabetes. Cell (1997) 90(2):303–13. doi:10.1016/S0092-8674(00)80338-4

72. Codina-Busqueta E, Scholz E, Munoz-Torres PM, Roura-Mir C, Costa M, Xufre C, et al. TCR bias of in vivo expanded T cells in pancreatic islets and spleen at the onset in human type 1 diabetes. J Immunol (2011) 186(6):3787–97. doi:10.4049/jimmunol.1002423

73. Conrad B, Weidmann E, Trucco G, Rudert WA, Brehm R, Ricordi C, et al. Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature (1994) 371(6549):351–5. doi:10.1038/371351a0

74. Meylan F, De Smedt M, Leclercq G, Plum J, Leupin O, Marguerat S, et al. Negative thymocyte selection to HERV-K18 superantigens in humans. Blood (2005) 105(10):3577–84. doi:10.1182/blood-2004-07-2586

75. Crudo A, Petropoulos S, Suderman M, Mouisias VG, Kostaki A, Hallett M, et al. Effects of antenatal synthetic glucocorticoid on glucocorticoid receptor binding, DNA methylation, and genome-wide mRNA levels in the fetal male hippocampus. Endocrinology (2013) 154(11):4170–81. doi:10.1210/en.2013-1484

76. Sun Y, Wan X, Ouyang J, Xie R, Wang X, Chen P. Prenatal dexamethasone exposure increases the susceptibility to autoimmunity in offspring rats by epigenetic programming of glucocorticoid receptor. Biomed Res Int (2016) doi:10.1155/2016/9409452

77. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell (2014) 157(12):1–41. doi:10.1016/j.cell.2014.03.011

78. Cortese R, Lu L, Yu Y, Ruden D, Clau E. Epigenome-microbiome crosstalk: a potential new paradigm influencing neonatal susceptibility to disease. Epigenetics (2016) 11(3):205–15. doi:10.1080/15592294.2016.1155011

79. King C, Sarvetnick N. The incidence of type-1 diabetes in NOD mice is modulated by restricted flora germ-free conditions. PLoS One (2011) 6(2):e17049. doi:10.1371/journal.pone.0017049

80. Marino E, Richards JL, McLeod KH, Stanley D, Yap YA, Knight J, et al. Gut microbial metabolites limit the frequency of autoimmunity T cells and protect against type 1 diabetes. Nat Immunol (2017) 18(5):552–62. doi:10.1038/nii.2017.71

81. Jordan MS, Boezaete A, Reed AJ, Petrone AL, Hohenbeck AE, Lerman MA, et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol (2001) 2(4):301–6. doi:10.1038/38630

82. Rudra D, deRoos P, Chaudhry A, Niec RE, Arvey A, Samstein RM, et al. Transcription factor Foxp3 and its protein partners form a complex regulatory network. Nat Immunol (2012) 13(10):1010–9. doi:10.1038/nii.2402

83. Karagiannidis C, Akdis M, Holopainen P, Woolley NJ, Hense G, Ruckert B, et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol (2004) 114(6):1425–33. doi:10.1016/j.jaci.2004.07.014

84. Konkel JE, Jin W, Abbbatiello B, Grainger JR, Chen W. Thymocyte apoptosis drives the intrathymic generation of regulatory T cells. Proc Natl Acad Sci U S A (2014) 111(4):E65–73. doi:10.1073/pnas.1302019111

85. Heninger AK, Eugster A, Kuehn D, Buettner F, Kuhn M, Lindner A, et al. A divergent population of autantigen-responsive CD4+ T cells in infants prior to beta cell autoimmunity. Sci Transl Med (2017) 9(378). doi:10.1126/scitranslmed.aaf8848

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Gieras, Gehbauer, Ferna-Barrull, Engler, Diepenbruck, Blau, Joosse, Kersten, Kleinge, Mittrüber, Friesel, Vives-Pi and Tolosa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.